Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …

Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting
up to 5% of the population. VTE commonly manifests as lower-extremity deep venous …

Thromboembolism in people with cancer still remains a major health problem and is a
leading cause of mortality after cancer itself, despite being a largely preventable disease. 1 …

Hemostasis and thrombosis are believed to be so intricately linked that any strategies that
reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is …

Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism,
is a chronic illness that affects nearly 10 million people every year worldwide. Strong …

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from
anticancer medications and represents an important limitation for the use of antithrombotic …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …

Patients with cancer-associated thrombosis (CAT) are at high risk of recurrent venous
thromboembolism (VTE) and major bleeding complications. Risks vary significantly between …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …